Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

GAITHERSBURG, Md., Aug. 23 /PRNewswire/ -- MedImmune, Inc. today announced that in a Phase 3 study, motavizumab was shown to reduce hospitalizations due to respiratory syncytial virus (RSV) by 83 percent as compared to placebo (8.3 percent in placebo arm vs. 1.4 percent in motavizumab; p<0.001), as the trial's primary endpoint. In addition, the trial showed a 71-percent reduction in the incidence of RSV-specific lower respiratory infections (LRIs) requiring outpatient management (9.5 percent in placebo group and 2.8 percent in the motavizumab group; p<0.001), which was a secondary endpoint.

Motavizumab is an investigational monoclonal antibody (MAb) being evaluated for its potential to prevent serious disease caused by RSV in high-risk pediatric patients. This Phase 3 trial involved 1,410 full-term infants less than six months of age in two Native American populations. In previous medical studies these populations were shown to have high rates of hospitalization due to RSV.

The randomized (2:1), double-blind study was designed to compare monthly intramuscular injections of motavizumab against placebo. After an interim analysis conducted by an independent data safety monitoring committee, the study was unblinded early due to statistical evidence demonstrating that motavizumab reduced RSV hospitalizations and LRIs requiring outpatient medical management within this population. Kate O'Brien, M.D., associate professor at the Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, served as the study's principal investigator.

"We are pleased with the results of this study which support the positive results seen in our Phase 3 pivotal trial comparing motavizumab and Synagis(R) (palivizumab) that were previously reported at the Pediatric Academic Societies meeting in May 2007," said Genevieve Losonsky, M.D., vice president, clinical development, infectious disease, MedImmune.

Motavizumab was well tolerated in these
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... , Aug. 3, 2015  Isis Pharmaceuticals, ... announced a strategic collaboration to discover and develop ... The new collaboration builds on a broad existing ... strategic approach in these therapeutic areas using novel ... extend use of its antisense technology to diseases ...
(Date:8/2/2015)... Mandatory takeover offer for ... or the "Company") is pleased to announce the signing ... Marijan Han žeković to acquire his 63.3% holding ... a Croatian listed pharmaceutical business.   Dechra ... to €51.4 million for the entire share capital on ...
(Date:8/2/2015)... Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... TELESTAR Phase 3 clinical trial met its primary ... in treating cancer patients with carcinoid syndrome that ... of care. Telotristat etiprate was discovered using Lexicon,s ... is the company,s first discovery to complete a ...
Breaking Medicine Technology:AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 2Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6
(Date:7/31/2015)... Indianapolis, Ind. (PRWEB) , ... August 01, 2015 , ... ... of the Global Advisory Panel on the Future of Nursing (GAPFON) 20-21 July 2015 ... were invited to participate in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and ...
(Date:7/31/2015)... ... ... Ticket Down is a reliable source for authentic tickets for the 2015 ... The festival will end on Sunday, August 2nd. , Music fans have ... This unique and unbelievably popular festival attracts the best in entertainment from around the ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently ... know in predictive health analytics , Jvion continues to disrupt the predictive ... predictive software that targets patient and population level illness to drive prevention and ...
(Date:7/31/2015)... Tenn. (PRWEB) , ... July 31, 2015 , ... The ... Robert Church Park in Downtown Memphis on October 3, 2015. The Ride to Fight ... focused on cancer research between Methodist Healthcare, The West Clinic and The University of ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... There’s no ... possible, even when it comes time to cook the next meal, making July the ... July by practicing best grilling tips and recipes. , Make the next cookout different ...
Breaking Medicine News(10 mins):Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3
... HealthDay Reporter , FRIDAY, Dec. 9 (HealthDay News) -- For ... of entertainment. But for Katie Sweeney and her family, a ... "It was absolute redemption," said Sweeney, recalling the afternoon in ... 14-year-old son Dusty -- who has autism -- caught a ...
... and Dissemination (CRD) at the University of York and ... new online service provided by the National Center for ... Medicine (NLM) the world,s largest medical library. The ... reviews and also provides information for consumers and clinicians ...
... From their fourth-floor state-of-the-art laboratory in the heart of ... and students help keep the feet of joint replacement ... opens this week, houses one of the country,s largest ... other artificial joints that were removed from patients, in ...
... A study on the geographic mobility of registered nurses (RNs) ... suggests that the profession,s relative lack of mobility has serious ... areas. According to the studypart of the RN Work ... (52.5 percent) of newly licensed RNs work within 40 miles ...
... a certain form of inherited hearing loss have ... a study by Professor Thomas Jentsch of the ... Molecular Medicine (MDC) Berlin-Buch and Professor Gary Lewin ... Spain and Nijmegen, the Netherlands. The research findings, ...
... by the Swiss researchers and published in Nature ... brain. Anxiety disorders constitute a complex family of ... from such disorders fear certain situations or objects to ... danger they present. The amygdala, a deep-brain structure, ...
Cached Medicine News:Health News:Broadway Strikes an Autism-Friendly Chord 2Health News:Broadway Strikes an Autism-Friendly Chord 3Health News:Broadway Strikes an Autism-Friendly Chord 4Health News:Clemson University opens bioengineering research lab at Greenville hospital campus 2Health News:Clemson University opens bioengineering research lab at Greenville hospital campus 3Health News:New registered nurses' lack of geographic mobility has negative implications for rural health 2Health News:New registered nurses' lack of geographic mobility has negative implications for rural health 3Health News:People with DFNA2 hearing loss show increased touch sensitivity 2Health News:People with DFNA2 hearing loss show increased touch sensitivity 3Health News:The cortex plays an essential part in emotional learning 2
... verification and laboratory specimen labeling system uses bar ... or nurse, the identity of the patient and ... made, a bar coded sample ID label is ... simplifies and eliminates the interface problems inherent with ...
... Bridge™ Specimen Collections, a Cerner ... for specimen identification and collection. The ... of the specimen collections process by ... and clinical information system integration to ...
... Horizon Admin-Rx is a bar-code medication ... the medication administration process with bar-code technology. ... a handheld or laptop device to verify ... medication at the right time in the ...
... Korchek Technologies CareChek ... employs barcode technology, Windows ... with integrated scanners (to ... at the bedside) and ...
Medicine Products: